Ameriprise
BTAI icon

Ameriprise’s BioXcel Therapeutics BTAI Stock Holding History

Ameriprise’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-36,198
Closed -$1.63M – 3868
2024
Q1 		$1.63M Buy
36,198
+2,381
+7% +$114K ﹤0.01% 2971
2023
Q4 		$1.6M Sell
33,817
-7,956
-19% -$442K ﹤0.01% 2986
2023
Q3 		$1.69M Buy
41,773
+19,932
+91% +$2.01M ﹤0.01% 2902
2023
Q2 		$2.33M Buy
+21,841
New +$7.27M ﹤0.01% 2800

Other funds holding BTAI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Ameriprise's BTAI Position: Q2 2024 in Review

Ameriprise sold out of BioXcel Therapeutics (BTAI) in Q2 2024, closing a stake of 36,198 shares — an estimated $1.63M sold.

Ameriprise first reported a position in BTAI in Q2 2023 and held it in 4 quarters. The position peaked at $2.33M in Q2 2023. 74 funds tracked by Wall St. Rank hold BTAI as of Q2 2024.

  • Ameriprise reported no remaining BioXcel Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Ameriprise sold 36,198 BioXcel Therapeutics shares in Q2 2024, an estimated $1.63M.
  • Ameriprise first reported a position in BioXcel Therapeutics in Q2 2023 and held it in 4 quarters.
  • Ameriprise's BioXcel Therapeutics position peaked at $2.33M in Q2 2023.
  • 74 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2024.

Based on Ameriprise's 13F filing for Q2 2024, filed 14 Aug 2024.